Atlas Trials

Comparison of Serplulimab Versus Nivolumab in Neoadjuvant Therapy for Resectable Stage II-IIIA Squamous NSCLC

Clinical trial NCT07398937 · RECRUITING

Trial details

NCT number
NCT07398937
Sponsor
Fudan University
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Resectable Stage II-IIIa Squamous NSCLC
Start date
2026-02-05
Primary completion
2027-12-31
Enrollment
116

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.